RSC Desktop Seminar Lectureship Series with RSC Medicinal Chemistry

4 August 2022 13:00-14:30, Online, United Kingdom

Welcome to the latest RSC Desktop Seminar Lectureship with RSC Medicinal Chemistry.

The RSC is proud to recognise exceptional scientists through our series of journal lectureships. The RSC Desktop Seminar Lectureship Series, featuring virtual talks by our recent journal lectureship winners, is an effort to expand access for researchers around the world looking to connect to some of the leading minds in the chemical sciences. Further information about all events in the series is available at

This 90 minute webinar will feature our 2021 and 2022 RSC Medicinal Chemistry Emerging Investigator Lectureship winners, Dr Jacob Bush and Dr Nir London, who will talk about their latest research, with an introduction by RSC Medicinal Chemistry Executive Editor, Becky Garton.

  • Dr Jacob Bush (GSK & Francis Crick Institute, UK), 2021 RSC Medicinal Chemistry Emerging Investigator Lectureship recipient
  • Dr Nir London (Weizmann Institute of Science, Israel), 2022 RSC Medicinal Chemistry Emerging Investigator Lectureship recipient


13.00 (BST) - Introduction by Becky Garton

13.10 - "Reactive fragment platforms for expansion of the liganded proteome," Dr Jacob Bush (GSK & Francis Crick Institute, UK)
2021 RSC Medicinal Chemistry Emerging Investigator Lectureship recipient

13. 45 - “Covalent Ligand Directed Release Chemistry,” Dr Nir London (Weizmann Institute of Science, Israel)
2022 RSC Medicinal Chemistry Emerging Investigator Lectureship recipient

14. 20 - Final Q&A and Closing Remarks
Dr Jacob Bush, GSK & Francis Crick Institute, United Kingdom

Dr Jacob Bush is a Director in the Chemical Biology Department at GSK and sits on the leadership team of the GSK-Francis Crick Institute Biomedical LinkLabs collaboration.  Prior to joining GSK, Jake completed a degree in chemistry from the University of Oxford and a DPhil in chemical biology in the laboratory of Professor Christopher Schofield. With an interest for translational science, he joined GSK in 2015 to explore ways to accelerate drug discovery through innovations in chemical biology and machine learning. Recently, the GSK-Crick team received an EPSRC Prosperity Partnership grant to build a Systems Chemical Biology Platform that brings together reactive fragments, chemoproteomics, high-content biology and AI/ML. The platform is being applied in disease relevant models to expand the liganded proteome and generate insights into opportunities for therapeutic intervention.

Dr Nir London, Weizmann Institute of Science, Israel

Dr. Nir London completed his PhD in computational structural biology at the Hebrew University in 2012. He then pursued a post-doctoral fellowship with Brian Shoichet at UCSF where he developed a pioneering virtual screening platform for covalent inhibitor discovery. In 2015 Dr. London joined the Weizmann Institute of Science, where he is currently the Alan and Laraine Fischer Career Development Chair in the Dept. of Chemical and Structural Biology. Dr. London’s lab is focused on covalent chemical biology and drug discovery and is developing new technologies to discover and functionalise covalently acting compounds. His honors include amongst others the Alon fellowship, the EFMC award for young medicinal chemist in academia and the ICBS award for young chemical biologist.

Zoom Webinar

Zoom Webinar, Online, United Kingdom

Organised by
RSC Medicinal Chemistry
Contact information
Showing all upcoming events
Start Date
End Date
Subject area
Event type


E-mail Enquiry